688067.SHG AVE Science & Technology Co Ltd
- Market cap
- CNY 1.41B
- P/E
- 41.6x
- P/B
- 2.47x
- ROE
- 8.3%
- Dividend yield
- 0.73%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688067.SHG undervalued?
Graham number688067.SHG trades 113.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AVE Science & Technology Co Ltd fundamental analysis
No fundamental analysis for AVE Science & Technology Co Ltd yet.
AVE Science & Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AVE Science & Technology Co Ltd
AVE Science&Technology CO.,LTD researches, develops, manufactures, markets, and services medical devices, biological reagents, remote medical diagnosis network, computer software, automatic control devices, and medical auxiliary equipment. It provides urine formed elements analyzers and related reagents, automatic urine analyzers, multi-function microscopy analyzers, semi-automatic biochemical analyzers, feces analyzers, and vaginal secretion analyzers; and reagents and cons…
Full company profileAVE Science & Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AVE Science & Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 117M | 136M | 151M | 190M | 180M | 211M | 197M | 200M | 203M | 230M | 234M |
| Gross Profit | 77.7M | 89.4M | 97.5M | 127M | 106M | 124M | 106M | 113M | 121M | 230M | 143M |
| Operating Income | 22.0M | 30.8M | 30.2M | 57.5M | 34.4M | 34.2M | 18.5M | 22.4M | 23.6M | 30.1M | 44.2M |
| EBITDA | 36.6M | 34.8M | 34.7M | 61.9M | 39.2M | 40.7M | 27.3M | 33.2M | 34.8M | 41.3M | 44.2M |
| Net Income | 30.3M | 27.4M | 27.3M | 50.5M | 30.1M | 31.3M | 18.0M | 21.5M | 22.8M | 28.9M | 45.2M |
| EPS | 0.59 | 0.54 | 0.53 | 0.99 | 0.59 | 0.53 | 0.26 | 0.32 | 0.34 | 0.43 | 0.66 |
| Balance Sheet | |||||||||||
| Total Assets | 211M | 224M | 258M | 297M | 297M | 548M | 550M | 557M | 561M | 580M | 633M |
| Total Liabilities | 33.5M | 34.1M | 40.4M | 44.9M | 59.9M | 70.0M | 74.5M | 66.8M | 65.2M | 65.8M | 91.7M |
| Shareholders' Equity | 178M | 190M | 217M | 253M | 237M | 478M | 475M | 490M | 496M | 514M | 542M |
| Cash & Short-term Investments | 47.8M | 24.5M | 43.0M | 33.5M | 59.8M | 293M | 277M | 87.8M | 71.6M | 47.7M | 72.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 31.2M | 24.8M | 40.4M | 62.1M | 46.9M | 47.2M | 29.7M | 22.7M | 22.4M | 41.5M | - |
| Capital Expenditure | 22.5M | 48.1M | 17.4M | 24.5M | 11.8M | 20.5M | 21.2M | 4.50M | 3.75M | 3.21M | 3.87M |
| Free Cash Flow | 8.73M | -23.3M | 23.0M | 37.6M | 35.1M | 26.7M | 8.54M | 18.2M | 18.7M | 38.3M | 21.1M |
| Ratios | |||||||||||
| ROE | 17.0% | 14.4% | 12.6% | 20.0% | 12.7% | 6.5% | 3.8% | 4.4% | 4.6% | 5.6% | 8.3% |
| ROA | 14.3% | 12.2% | 10.6% | 17.0% | 10.1% | 5.7% | 3.3% | 3.9% | 4.1% | 5.0% | 7.1% |
| Net Profit Margin | 25.9% | 20.2% | 18.1% | 26.6% | 16.7% | 14.8% | 9.1% | 10.8% | 11.2% | 12.6% | 19.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AVE Science & Technology Co Ltd dividends
- Dividend yield
- 0.73%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 35.8%
- Ex-dividend date
- Jul 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 10.4M | 0.15 | 35.8% |
| 2024 | CNY 6.80M | 0.10 | 29.8% |
| 2023 | CNY 6.80M | 0.10 | 31.6% |
| 2022 | CNY 20.4M | 0.30 | 113.5% |
| 2021 | - | - | - |
| 2020 | CNY 45.9M | 0.90 | 152.5% |
| 2019 | CNY 15.3M | 0.30 | 30.3% |
| 2018 | - | - | - |
| 2017 | 10.2M | 0.20 | 37.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AVE Science & Technology Co Ltd
- Insiders 55.75%
- Institutions 5.33%
- Public & others 38.92%
- Shares outstanding 68.0M
- Free float 32.4M
AVE Science & Technology Co Ltd company profile
- Company name
- AVE Science & Technology Co Ltd
- Ticker
- 688067.SHG
- ISIN
- CNE100005188
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 510
- Fiscal year end
- December
- Address
- No. 26, Fuling Road, Changsha, China, 410208
- Phone
- 86 731 8892 5308
- Website
- c-ave.com
About AVE Science & Technology Co Ltd
AVE Science&Technology CO.,LTD researches, develops, manufactures, markets, and services medical devices, biological reagents, remote medical diagnosis network, computer software, automatic control devices, and medical auxiliary equipment. It provides urine formed elements analyzers and related reagents, automatic urine analyzers, multi-function microscopy analyzers, semi-automatic biochemical analyzers, feces analyzers, and vaginal secretion analyzers; and reagents and consumables comprising reagent packs, test strips, urine analyzer cleansers, urine sample collectors, and urine formed elements analyzer quality control products. It serves customers in China, Europe, the United States, Asia, Africa, and internationally. AVE Science&Technology CO.,LTD was incorporated in 2000 and is headquartered in Changsha, China.
AVE Science & Technology Co Ltd management
5- Mr. Jianwen DingGM & Chairman · born 1957
- Mr. Kunxiang LongCFO & Accounting Supervisor · born 1974
- Mr. Changqing LinDeputy GM & Director · born 1972
- Mr. Fengliang ZhouDeputy GM & Director · born 1965
- Mr. Hui Jie YuanSecretary to the Board · born 1992